ARTIST 2随机III期试验:D2切除后淋巴结阳性胃癌的辅助S-1、SOX与SOXRT比较
ARTIST 2试验在D2切除的II/III期淋巴结阳性胃癌患者中,1:1:1随机比较口服S-1单药1年、SOX方案6个月和SOX联合放化疗(SOXRT)三种辅助方案。主要终点为3年无病生存(DFS)。共入组546例,中位随访47个月。SOX较S-1显著延长DFS(HR 0.692,P=0.042),SOXRT较S-1未达显著(HR 0.724,P=0.074),SOX与SOXRT无差异(HR 0.971,P=0.879)。
要点
- D2切除后淋巴结阳性胃癌辅助SOX较S-1单药显著改善3年DFS。
- SOX基础上加放疗未显著降低复发(SOX vs SOXRT HR 0.971,P=0.879)。
- SOXRT较S-1的DFS获益未达统计学显著(HR 0.724,P=0.074)。
核心结论
- 在D2切除的II/III期淋巴结阳性胃癌中,辅助SOX或SOXRT较S-1单药延长DFS。
- SOX基础上加放疗未显著降低D2胃切除术后复发率。
研究设计与样本
- 随机III期试验,1:1:1分配至S-1、SOX、SOXRT三组。
- 入组546例D2切除、II/III期、淋巴结阳性胃癌患者,S-1组182例、SOX组181例、SOXRT组183例。
- 随机分层因素为手术类型(全胃或次全胃切除)、病理分期(II或III期)、Lauren组织学分类(弥漫型或肠型/混合型)。
- 主要终点为3年DFS,以SOX或SOXRT较S-1的DFS风险比降低33%为临床有意义。
主要发现
- 中位随访47个月,共观察178例DFS事件。
- 3年DFS率:S-1组64.8%、SOX组74.3%、SOXRT组72.8%。
- DFS风险比:S-1 vs SOX为0.692(P=0.042);S-1 vs SOXRT为0.724(P=0.074)。
- SOX vs SOXRT的DFS风险比为0.971(P=0.879)。
- 不良事件在各组符合预期,总体耐受良好且可控。
关键数值与推荐
- S-1用法:口服40-60 mg每日两次,服4周停2周,共1年。
- SOX用法:S-1服2周停1周,联合奥沙利铂130 mg/m2每3周一次,共6个月。
- SOXRT用法:SOX方案联合放疗45 Gy。
临床怎么用
- 对于D2切除后II/III期淋巴结阳性胃癌,可考虑辅助SOX作为S-1单药之外的选项。
- SOX基础上加放疗未显示显著DFS获益,不支持常规联合放疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adjuvant chemotherapy and chemoradiotherapy are some of the standards of care for gastric cancer (GC). The Adjuvant chemoRadioTherapy In Stomach Tumors (ARTIST) 2 trial compares two adjuvant chemotherapy regimens and chemoradiotherapy in patients with D2-resected, stage II or III, node-positive GC. PATIENTS AND METHODS: The ARTIST 2 compared, in a 1:1:1 ratio, three adjuvant regimens: oral S-1 (40-60 mg twice daily 4 weeks on/2 weeks off) for 1 year, S-1 (2 weeks on/1 week off) plus oxaliplatin 130 mg/m2 every 3 weeks (SOX) for 6 months, and SOX plus chemoradiotherapy 45 Gy (SOXRT). Randomization was stratified according to surgery type (total or subtotal gastrectomy), pathologic stage (II or III), and Lauren histologic classification (diffuse or intestinal/mixed). The primary endpoint was disease-free survival (DFS) at 3 years; a reduction of 33% in the hazard ratio (HR) for DFS with SOX or SOXRT, when compared with S-1, was considered clinically meaningful. The trial is registered at clinicaltrials.gov (NCT0176146). RESULTS: A total of 546 patients were recruited between February 2013 and January 2018 with 182, 181, and 183 patients in the S-1, SOX, and SOXRT arms, respectively. Median follow-up period was 47 months, with 178 DFS events observed. Estimated 3-year DFS rates were 64.8%, 74.3%, and 72.8% in the S-1, SOX, and SOXRT arms, respectively. HR for DFS in the control arm (S-1) was shorter than that in the SOX and SOXRT arms: S-1 versus SOX, 0.692 (P = 0.042) and S-1 versus SOXRT, 0.724 (P = 0.074). No difference in DFS was found between SOX and SOXRT (HR 0.971; P = 0.879). Adverse events were as anticipated in each arm, and were generally well-tolerated and manageable. CONCLUSIONS: In patients with curatively D2-resected, stage II/III, node-positive GC, adjuvant SOX or SOXRT was effective in prolonging DFS, when compared with S-1 monotherapy. The addition of radiotherapy to SOX did not significantly reduce the rate of recurrence after D2 gastrectomy.
引用
- Park SH, Lim DH, Sohn TS, et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆. Ann Oncol. 2020. PMID: 33278599. doi:10.1016/j.annonc.2020.11.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。